Identifying the missing link in inflammatory signaling
Identifying the missing link in inflammatory signaling
批准号:
9807309
负责人:
ELAN Z EISENMESSER
金额:
$23.33万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-02 至 2021-08-31
关键词:
AddressAnti-inflammatoryBiochemicalBiologicalBiophysicsBreastCellsCellular MembraneColorectalComplexComputer SimulationConflict (Psychology)CysteineDataDisulfidesDockingEnvironmentEventFamilyFoundationsGenerationsGoalsHeterodimerizationHomoHomodimerizationHumanIndividualInflammationInflammatoryInflammatory ResponseInnate Immune ResponseInterleukin ReceptorInterleukin-1 ReceptorsLigandsLinkLiverMalignant NeoplasmsMalignant neoplasm of lungMediatingModelingMolecularNatural ImmunityOrangesOrganismOrphanOxidation-ReductionOxidative StressPharmaceutical PreparationsPharmacologyProstateReceptor SignalingRecombinantsRoleSignal TransductionStomachStructureSurfaceTLR1 geneTLR2 geneTLR4 geneTherapeuticTherapeutic InterventionToll-like receptorsYersinia pestisbaseintimate behaviormembernoveloverexpressionreceptorreceptor-mediated signalingtumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
The Nobel winning discoveries of Toll-like Receptors (TLRs) and interleukin-1 receptors (IL-1Rs) have
revolutionized our understanding of inflammation and oncogenesis, which makes it surprising that the initiating
intracellular events still remain poorly characterized. Specifically, both receptor families share common
intracellular Toll/Interleukin-Receptor (TIR) domains that engage adaptor TIR domains in order to initiate
signaling, yet no human oligomeric TIR complex has been structurally observed. Instead, the TIR interactome
has almost exclusively been extrapolated from structures of individual TIR domains and computational
modeling, often resulting in conflicting data. Thus, despite the nearly two decades since the first structural
characterization of the TIR domains of TLR1 and TLR2 receptors, the molecular mechanisms that underlie the
critical roles of TIR signaling remains unknown. Our goals are to determine the molecular basis of TIR domain
interactions that underlie the innate immune response, thereby bridging the initiating events on the outside of
the cell with downstream events that drive inflammation.
The novelty in our approach is our combination of biochemical, biophysical, and biological studies along
with our unique ability to recombinantly produce multiple human TIR members, which has revealed a surprising
underlying molecular mechanism of TLR interactions. Namely, we have discovered that TLR1/TLR2
homodimer and heterodimer formation are mediated by an intermolecular disulfide exchange of a conserved
cysteine found in all TLRs expressed on the cellular surface. Such a signaling mechanism, referred to as
“dock-and-lock”, has only been observed for PDZ domains that also form signaling complexes at the cellular
membrane. However, disulfide mediated TIR interactions have been observed in other organisms and a drug
specific for the same conserved cysteine within TLR4 blocks its activity. Such studies highlight the importance
of determining the molecular mechanism of TLR interactions that would also provide a basis for
pharmacologically blocking their interactions through targeting of this conserved cysteine. Interestingly, our
preliminary studies also suggest that the anti-inflammatory activity of the orphaned IL-1R8 receptor blocks
TLR1/TLR2 interactions through a similar “dock-and-lock” mechanism, providing the molecular basis for one of
the most exciting negative regulators of inflammation within the last 15 years.
Based on these preliminary studies, we hypothesize that a conserved cysteine mediates complex
formation of TLR1, TLR2, and IL-1R8 through a “dock-and-lock” mechanism. The versatility in
homo/heterodimerization results in varied downstream TIR interactions that fine-tune the cellular inflammatory
response. We will address this hypothesis through the following Specific Aims:
Aim 1) Determine the molecular basis of TLR1/TLR2 TIR homodimerization and heterodimerization and
how their specific interactions regulate cellular signaling.
Aim 2) Determine how IL-1R8 TIR blocks TLR1/TLR2 TIR interactions and how such interactions
modulate downstream adaptor interactions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SARS-CoV-2 N interactions with RNA and host cell cyclophilin-A
-
批准号:10349084
-
项目类别:
-
资助金额:$19.44万
-
财政年份:2022
-
负责人:ELAN Z EISENMESSER
-
依托单位:
SARS-CoV-2 N interactions with RNA and host cell cyclophilin-A
-
批准号:10622478
-
项目类别:
-
资助金额:$23.33万
-
财政年份:2022
-
负责人:ELAN Z EISENMESSER
-
依托单位:
Diversity Supplement R01GM139892 - Lorena Alamillo
-
批准号:10811189
-
项目类别:
-
资助金额:$7.96万
-
财政年份:2021
-
负责人:ELAN Z EISENMESSER
-
依托单位:
The global regulation of dynamics and structure mediated by single hydride in a family of reductases
-
批准号:10296136
-
项目类别:
-
资助金额:$30.28万
-
财政年份:2021
-
负责人:ELAN Z EISENMESSER
-
依托单位:
The global regulation of dynamics and structure mediated by single hydride in a family of reductases
-
批准号:10656573
-
项目类别:
-
资助金额:$30.23万
-
财政年份:2021
-
负责人:ELAN Z EISENMESSER
-
依托单位:
Determining how the giant Streptococcus Pneumoniae IgA1 protease cleaves its host IgA1 substrate and how this interaction can be blocked
-
批准号:9896366
-
项目类别:
-
资助金额:$19.44万
-
财政年份:2019
-
负责人:ELAN Z EISENMESSER
-
依托单位:
Combining chemical shift-based and experimental approaches to study enzyme dynami
-
批准号:8693572
-
项目类别:
-
资助金额:$29.15万
-
财政年份:2014
-
负责人:ELAN Z EISENMESSER
-
依托单位:
Combining chemical shift-based and experimental approaches to study enzyme dynami
-
批准号:9261551
-
项目类别:
-
资助金额:$29.24万
-
财政年份:2014
-
负责人:ELAN Z EISENMESSER
-
依托单位:
EMMPRIN: from biology to molecular mechanism
-
批准号:8106630
-
项目类别:
-
资助金额:$28.67万
-
财政年份:2011
-
负责人:ELAN Z EISENMESSER
-
依托单位:
EMMPRIN: from biology to molecular mechanism
-
批准号:8241002
-
项目类别:
-
资助金额:$28.66万
-
财政年份:2011
-
负责人:ELAN Z EISENMESSER
-
依托单位:
EMMPRIN: from biology to molecular mechanism
-
批准号:8643256
-
项目类别:
-
资助金额:$28.63万
-
财政年份:2011
-
负责人:ELAN Z EISENMESSER
-
依托单位:
EMMPRIN: from biology to molecular mechanism
-
批准号:8450841
-
项目类别:
-
资助金额:$27.64万
-
财政年份:2011
-
负责人:ELAN Z EISENMESSER
-
依托单位:
海外基金